文献速递骨肿瘤关节外科

膝关节骨软骨同种异体骨移植失败后转换为巨假体与初次巨假体的结局比较

Do Patients Who Undergo Conversion of Failed Osteoarticular Allografts to Megaprostheses Have Worse Outcomes Than Patients Treated With Primary Megaprostheses at Initial Resection?
PubMed 文献 · Clin Orthop Relat Res · 2026-04-13

本研究比较骨软骨同种异体骨移植失败后转换为巨假体与初次巨假体置换的患者,经倾向性评分匹配后,两组在假体生存率、保肢率和功能结局(MSTS-93评分、膝关节屈曲角度、伸展滞后)上无显著差异,转换组在MSTS-93评分和伸展滞后方面非劣效于初次组。

要点

  • 转换巨假体与初次巨假体在5年和15年无翻修生存率及15年无截肢生存率无差异
  • 两组MSTS-93评分、膝关节屈曲角度和伸展滞后无显著差异
  • 胫骨近端置换中转换组伸展滞后优于初次组,且MSTS-93和伸展滞后非劣效

核心结论

  • 骨软骨同种异体骨移植失败后转换为巨假体在假体生存、保肢和功能结局上与初次巨假体无差异,是可靠的保肢补救方案。

研究设计与样本

  • 回顾性队列研究,纳入1997年至2023年276例股骨远端或胫骨近端骨肉瘤患者,经排除标准筛选后,转换组23例与初次组124例,经1:2倾向性评分匹配形成转换组23例和初次组46例。

主要发现

  • 转换组与初次组5年无翻修生存率分别为79%(95%CI 60%至98%)和75%(95%CI 61%至90%),15年分别为37%(95%CI 6%至67%)和49%(95%CI 25%至73%),p=0.61。
  • 转换组与初次组15年无截肢生存率分别为100%(95%CI 100%至100%)和92%(95%CI 81%至100%),p=0.29。
  • 转换组与初次组MSTS-93评分分别为23±4和25±5(平均差1,95%CI -1至4,p=0.17),膝关节屈曲角度分别为94°±24°和104°±19°(p=0.17),伸展滞后分别为3°±3°和6°±9°(p=0.21)。
  • 胫骨近端置换中转换组与初次组伸展滞后分别为5°±4°和13°±12°(p=0.01)。
  • 非劣效性检验显示转换组MSTS-93评分和伸展滞后非劣效于初次组(15%界值)。

临床怎么用

  • 对于年轻、合并症少、依从性好的骨肿瘤患者,骨软骨同种异体骨移植可作为争取时间的策略,失败后转换为巨假体不损害后续生存和功能。

局限性

  • 回顾性设计,转换组样本量较小(23例),随访时间较长但存在失访,非劣效性检验的界值设定可能影响解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Osteoarticular allografts are used for knee reconstruction after tumor resection, but the number of these types of reconstruction has declined because of frequent complications and perceived better results with tumor endoprostheses. Failed osteoarticular allografts can be salvaged with megaprosthesis conversion, but it remains unclear whether the outcomes of the patients who undergo conversion differ from those of patients who have primary megaprosthesis reconstructions at the time of tumor resection. Also, there is lack of evidence on the comparison of implant survival. This study aimed to fill the gaps in our current knowledge about conversion megaprosthesis to inform patients and guide treatment accordingly. QUESTIONS/PURPOSES: (1) Did the survivorship free from revision or amputation differ between patients who initially received an osteoarticular allograft and underwent a conversion to a megaprosthesis and patients who underwent primary megaprosthesis reconstruction? (2) Did the groups differ in terms of Musculoskeletal Tumor Society-93 (MSTS-93) scores, knee flexion angle, and extensor lag? METHODS: Between January 1997 and December 2023, we treated 276 patients with megaprosthesis for bone sarcoma of the distal femur and proximal tibia, including patients who had a failed osteoarticular allograft in the distal femur or proximal tibia and were subsequently converted to megaprosthesis as well as patients who initially underwent megaprosthesis reconstruction. At our institution, initial patient selection for osteoarticular allograft reconstruction is influenced by several factors. Patients who were younger, had fewer comorbidities, and who would be more compliant with the follow-up protocol usually underwent osteoarticular allograft reconstruction for the initial resection procedure. All patients were followed up for at least 2 years after megaprosthesis reconstruction or until reoperation or death (mean ± SD follow-up time 10 ± 8 years). The patient cohort in the institutional database had 29 patients with conversion before the exclusion criteria were applied. Seven percent (2 of 29) of the patients underwent conversion with different implant systems and 14% (4 of 29) of the patients had insufficient follow-up. Seventy-nine percent (23 of 29) of the patients were eligible for final analysis. In the primary group, there were 247 patients before the exclusion criteria were applied. Twenty-one percent (52 of 247) of the patients underwent primary reconstruction with different implant systems, 6% (14 of 247) received uncemented stems, 2% (6 of 247) underwent extraarticular resection, and 1% (2 of 247) of the patients initially underwent allograft-prosthetic composite reconstruction. After the exclusion criteria were applied, 70% (173 of 247) of the patients were eligible. Of those patients, 20% (49 of 247) had insufficient follow-up. Fifty percent (124 of 247) of the patients were eligible for the final analysis. After 1:2 nearest-neighbor propensity score matching, 23 patients who underwent a conversion to endoprosthesis were compared with 46 patients who had a primary megaprosthesis implanted at the time of the tumor resection. Groups were matched for age, gender, BMI, diagnosis, tumor location, resection ratio, stem length, and stem diameter. After matching, osteosarcoma was the most common diagnosis for the conversion and primary groups (65% versus 70%, standardized mean difference [SMD] -0.09). Distal femur was the most common tumor location for the conversion and primary groups (70% versus 70%, SMD 0.00). We compared survivorship free from revision and survivorship free from amputation between patients with conversion and primary megaprostheses using competing risk analysis. Tumor recurrence and death were assessed as competing events for competing risk analysis. We then compared functional outcomes, including the MSTS-93 score, knee flexion angle, and extensor lag with the Welch t-test. Additionally, we performed a noninferiority test to evaluate whether patients with conversion had functional outcomes (MSTS-93 score, knee flexion angle, and extensor lag) not worse than the primary group with a 15% margin. In comparisons, MSTS-93 scores and knee flexion angles were regarded as clinically inferior in lower values, whereas extensor lag was regarded as clinically inferior in higher values. RESULTS: Survivorship free from revision did not differ between the conversion and primary groups at 5 years (79% [95% confidence interval (CI) 60% to 98%] versus 75% [95% CI 61% to 90%]) and at 15 years (37% [95% CI 6% to 67%] versus 49% [95% CI 25% to 73%]; p = 0.61). Survivorship free from amputations did not differ between the conversion and primary groups at 15 years (100% [95% CI 100% to 100%] versus 92% [95% CI 81% to 100%]; p = 0.29). Likewise, the conversion and primary groups did not differ in terms of MSTS-93 scores at mean ± SD 11 ± 8 years (23 ± 4 versus 25 ± 5, mean difference 1 [95% CI -1 to 4]; p = 0.17). The conversion and primary groups did not differ in terms of knee flexion angles at 11 ± 8 years (94° ± 24° versus 104° ± 19°; p = 0.17). The conversion and primary groups did not differ in terms of extensor lag at 11 ± 8 years (3° ± 3° versus 6° ± 9°; p = 0.21). The conversion and primary groups differed in terms of extensor lag in proximal tibia replacements (5° ± 4° versus 13° ± 12°; p = 0.01). Noninferiority was demonstrated for MSTS-93 scores and extensor lag for the conversion group. CONCLUSION: A conversion megaprosthesis yields outcomes no different than a primary megaprosthesis in terms implant survival, limb preservation, and functional outcomes. When limb salvage is feasible, a conversion megaprosthesis represents a reliable salvage option for failed osteoarticular allograft reconstruction. Our findings show that osteoarticular allografts around the knee continue to have a selective role as a time-buying strategy for younger patients with bone tumors without compromising future survival and outcomes. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Aksoy T, Mosher HA, Torralbas Fitz SJ, et al. Do Patients Who Undergo Conversion of Failed Osteoarticular Allografts to Megaprostheses Have Worse Outcomes Than Patients Treated With Primary Megaprostheses at Initial Resection? Clin Orthop Relat Res. 2026. PMID: 41974446. doi:10.1097/CORR.0000000000003937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。